Serious infections during anti-TNFα treatment in rheumatoid arthritis patients

Autoimmunity Reviews

Volumn 8, Issue 3, 2009, Pages 266-273

  Favalli, Ennio Giulio ^a   Desiati, Francesca ^a   Atzeni, Fabiola ^b   Sarzi Puttini, Piercarlo ^b   Caporali, Roberto ^c   Pallavicini, Francesca Bobbio ^c   Gorla, Roberto ^d   Filippini, Matteo ^d   Marchesoni, Antonio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d Rheumatology and Clinical Immunology Unit   (Italy)

Author keywords

Adalimumab; Anti TNF ; Etanercept; Infection; Infliximab; Rheumatoid arthritis; Safety

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; ISONIAZID; METHOTREXATE; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL INFECTION; ABSCESS; ACUTE CHOLECYSTITIS; ACUTE HEPATITIS; ADULT; AGED; ANTIBIOTIC THERAPY; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BONE INFECTION; BRONCHITIS; CELLULITIS; CHOLANGITIS; DISEASE DURATION; DISEASE REGISTRY; DRUG COMBINATION; EAR INFECTION; ERYTHROCYTE SEDIMENTATION RATE; EYE INFECTION; FEMALE; GASTROENTERITIS; GENITAL TRACT INFECTION; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION; INFECTIOUS ARTHRITIS; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOBACTERIOSIS; MYCOSIS; NEUROLOGICAL INFECTION; OSTEOMYELITIS; PARASITOSIS; PERICARDITIS; PERITONITIS; PNEUMONIA; PYELONEPHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SINUSITIS; SKIN INFECTION; SOFT TISSUE INFECTION; SUPPURATIVE APPENDICITIS; URINARY TRACT INFECTION; UROSEPSIS; VIRUS INFECTION; WOUND INFECTION;

ADRENAL CORTEX HORMONES; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; INCIDENCE; ITALY; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RADIOGRAPHY, THORACIC; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SHOCK, SEPTIC; SKIN TESTS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58749090375     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2008.11.002     Document Type: Review

References (36)

1. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindal E.A., Fleischmann R.M., Weaver A.L., et al. Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor (p75)-Fc fusion protein. N Engl J Med 337 (1997) 141-147
2. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354 (1999) 1932-1939
3. Weinblatt M.E., Keystone E.C., Furst D.E., Kavanaugh A.F., Chartash E.K., and Segurado O.G. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 65 (2006) 753-759
4. Klareskog L., van der Heijde D.M.F.M., de Jager J.P., Gough A., Kalden J., and Malaise M. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
5. Lipsky P.E., van der Heijde D.M.F.M., St Clair E.W., Furst D.E., Bredveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343 (2000) 1594-1602
6. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaun H., Hua Y., Teoh L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004) 1400-1411
7. Baum J. Infections in rheumatoid arthritis. Arthritis Rheum 14 (1971) 135-1357
8. Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., and Gabriel S.E. Frequency of infection in patients with rheumatoid arthritis compared with controls. A population-based study. Arthritis Rheum 9 (2002) 2287-2293
9. Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis?. J Rheumatol 32 Suppl 74 (2005) 35-39
10. Gómez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., Montero M.D., and for the BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 (2003) 2122-2127
11. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., Montero D., Pascual-Gomez E., Mola E.M., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52 (2005) 1766-1772
12. Kalyoncu U., Karadag O., Akdogan A., Kisacik B., Erman M., Erguven S., et al. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab. Scand J Infect Dis 39 (2007) 475-478
13. Lassoued S., Zabraniecki L., Marin F., and Billey T. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum 36 (2007) 262-263
14. Jain V.V., Evans T., and Peterson M.W. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area. Respir Med 100 (2006) 1291-1293
15. Fabre S., Gibert C., Lechiche C., Jorgensen C., and Sany J. Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab. J Rheumatol 32 (2005) 2432-2433
16. Salliot C., Gossec L., Ruyssen-Witrand A., Luc M., Duclos M., Guignard S., et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology 46 (2007) 327-334
17. Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52 (2005) 3403-3412
18. Dixon W.G., Watson K., Lunt K., Hyrich K.L., British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, and Symmons DPM. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthritis Rheum 54 (2006) 2368-2376
19. Curtis J.R., Patkar N., Xie A., Martin C., Allison J.J., Saag M., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 56 (2007) 1125-1133
20. Bernatsky S., Hudson M., and Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology 46 (2007) 1157-1160
21. Sarzi-Puttini P, Antivalle M, Marchesoni A, Favalli EG, Gorla R, Fillipini M, et al. Efficacy and safety of anti-TNF agents in the Lombardy Rheumatoid Arthritis Network (LORHEN). Reumatismo in press.
22. Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Antoni C.E., Bijlsma J.W.J., et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis 61 Suppl 2 (2002) 2 10.1136/ard.61.suppl_2.ii2
23. Dixon W.G., Symmons D.P., Lunt M., Watson K.D., Hyrich K.L., and Silman A.J. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 56 (2007) 2896-2904
24. Kroesen S., Widmer A.F., Tyndall A., and Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology 42 (2003) 617-621
25. Greene C., Lowe G., Taggart C., Gallagher P., McElvaney N., and O'Neill S. Tumor necrosis factor-α-converting enzyme: its role in community-acquired pneumonia. J Infect Dis 186 (2002) 1790-1796
26. Wolfe F., Caplan L., and Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia. Association with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54 (2006) 628-634
27. Groves R.W., Allen M.H., Ross E.L., Barker J.N., and MacDonald D.M. Tumour necrosis factor α is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol 132 (1995) 345-352
28. Khanna D., McMahon M., and Furst D.E. Safety of tumour necrosis factor-α antagonists. Drug Saf 27 (2004) 307324
29. Gardam M.A., Keystone E.C., Menzies R., Manners S., Skamene E., Long R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3 (2003) 148-155
30. Wallis R.S., Broder M.S., Wong J.Y., Hanson M.E., and Beenhouwer D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38 (2004) 1261-1265
31. The World Health Organization; 2005 [http://www.who.int/globalatlas/dataQuery].
32. Wallis R.S., and Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34 Suppl 1 (2005) 34-38
33. Fleischmann R., Iqbal I., Nandeshwar P., and Quiceno A. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf 25 (2002) 173-197
34. Keane J., Gershon S., Wise R.P., Mirable-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
35. Valesini G., Iannuccelli C., Marocchi E., Pascoli L., Scalzi V., and Di Franco M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 7 (2007) 35-41
36. Tincani A., Andreoli L., Bazzani C., Bosiso D., and Sozzani S. Inflammatory molecules: a target for treatment of systemic autoimmune diseases. Autoimmun Rev 7 (2007) 1-7